Abstract
Li Juan Sun, Wen Jing Fan, Zi Yi Shi, Yuan Jie Zhao, Yong Zhan Nie
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019
10.1016/s0140-6736(20)30925-9 · 2020
Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver
10.1002/hep.27210 · 2014
The Microbiota in Cirrhosis and Its Role in Hepatic Decompensation
10.1016/j.jhep.2020.11.013 · 2021
10.3390/ijms26020527
10.3390/ijms26020527
10.3389/fnut.2024.1337889
10.3389/fnut.2024.1337889
10.1186/s12967‐025‐06774‐y
10.1186/s12967‐025‐06774‐y
The Gut‐Brain Axis
10.1146/annurev-med-042320-014032 · 2022
Signals From the Gut Microbiota to Distant Organs in Physiology and Disease
10.1038/nm.4185 · 2016
10.1016/j.phrs.2024.107361
10.1016/j.phrs.2024.107361
Altered Serum Bile Acid Pattern as an Independent Factor for Covert and Overt Hepatic Encephalopathy in Patients With Cirrhosis
10.1111/hepr.70036 · 2026
10.1016/j.jhepr.2022.100448
10.1016/j.jhepr.2022.100448
Bile Acids and the Gut Microbiota: Metabolic Interactions and Impacts on Disease
10.1038/s41579-022-00805-x · 2023
Bile Acid–Microbiota Crosstalk in Gastrointestinal Inflammation and Carcinogenesis
10.1038/nrgastro.2017.119 · 2018
10.1080/21688370.2017.1373208
10.1080/21688370.2017.1373208
A Gut–Brain Axis Regulating Glucose Metabolism Mediated by Bile Acids and Competitive Fibroblast Growth Factor Actions at the Hypothalamus
10.1016/j.molmet.2017.12.003 · 2018
10.14814/phy2.13294
10.14814/phy2.13294
Bile Acids in Hepatic Encephalopathy
10.1016/j.jceh.2018.04.011 · 2019
FXR Agonists for MASH Therapy: Lessons and Perspectives From Obeticholic Acid
10.1002/med.21991 · 2024
Fto Deficiency Reduces Anxiety‐ and Depression‐Like Behaviors in Mice via Alterations in Gut Microbiota
10.7150/thno.31562 · 2019
Long Non‐Coding RNA ACTA2‐AS1 Promotes Ductular Reaction by Interacting With the p300/ELK1 Complex
10.1016/j.jhep.2021.12.014 · 2022
Microglia Take Centre Stage in Neurodegenerative Disease
10.1038/s41577-018-0112-5 · 2019
Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology
10.1007/s40265-018-1017-0 · 2019
Microbiota Transplant for Hepatic Encephalopathy in Cirrhosis: The THEMATIC Trial
10.1016/j.jhep.2024.12.047 · 2025
Microbiome Therapeutics for Hepatic Encephalopathy
10.1016/j.jhep.2021.08.004 · 2021
The Microbiota–Gut–Brain Axis and Neurodevelopmental Disorders
10.1093/procel/pwad026 · 2023
10.1016/j.bbadis.2024.167221
10.1016/j.bbadis.2024.167221
10.1016/j.ab.2021.114436
10.1016/j.ab.2021.114436
Farnesoid X Receptor Antagonizes Nuclear Factor κB in Hepatic Inflammatory Response
10.1002/hep.22519 · 2008
Farnesoid X Receptor Activation Inhibits Inflammation and Preserves the Intestinal Barrier in Inflammatory Bowel Disease
10.1136/gut.2010.212159 · 2011
FXR‐Mediated Regulation of eNOS Expression in Vascular Endothelial Cells
10.1093/cvr/cvm016 · 2008
Regulation of Antibacterial Defense in the Small Intestine by the Nuclear Bile Acid Receptor
10.1073/pnas.0509592103 · 2006
The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats
10.1016/j.ajpath.2014.10.009 · 2015
No additional external references are available.